New biosimilar shows promise for treating wet macular degeneration

NCT ID NCT04522167

Completed Disease control Sponsor: Bioeq GmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called FYB203, which is a biosimilar (a close copy) of the existing medication Eylea, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The trial involved 434 participants and compared how well FYB203 worked versus Eylea in improving vision over 8 weeks. The goal was to see if FYB203 is as safe and effective as Eylea, offering a potentially more affordable treatment option for this chronic eye condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Locations

Research Site

Sofia, Bulgaria
Research Site

Stara Zagora, Bulgaria
Research Site

Hradec Králové, Czechia
Research Site

Ostrava, Czechia
Research Site

Pardubice, Czechia
Research Site

Prague, Czechia
Research Site

Sokolov, Czechia
Research Site

Budapest, Hungary
Research Site

Debrecen, Hungary
Research Site

Pécs, Hungary
Research Site

Szeged, Hungary
Research Site

Székesfehérvár, Hungary
Research Site

Tatabánya, Hungary
Research Site

Zalaegerszeg, Hungary
Research Site

Haifa, Israel
Research Site

Jerusalem, Israel
Research Site

Kfar Saba, Israel
Research Site

Petah Tikva, Israel
Research Site

Rehovot, Israel
Research Site

Rishon LeZiyyon, Israel
Research Site

Tel Aviv, Israel
Research Site

Bologna, Italy
Research Site

Florence, Italy
Research Site

Milan, Italy
Research Site

Roma, Italy
Research Site

Rozzano, Italy
Research Site

Udine, Italy
Research Site

Akita, Japan
Research Site

Amagasaki, Japan
Research Site

Asahikawa, Japan
Research Site

Chiyoda City, Japan
Research Site

Chūō, Japan
Research Site

Fukuoka, Japan
Research Site

Fukushima, Japan
Research Site

Hamamatsu, Japan
Research Site

Himeji, Japan
Research Site

Hirakata, Japan
Research Site

Kita-ku, Japan
Research Site

Kurume, Japan
Research Site

Meguro City, Japan
Research Site

Nagasaki, Japan
Research Site

Nagoya, Japan
Research Site

Sapporo, Japan
Research Site

Shinjuku-Ku, Japan
Research Site

Suita, Japan
Research Site

Toride, Japan
Research Site

Yokosuka, Japan
Research Site

Bielsko-Biala, Poland
Research Site

Bydgoszcz, Poland
Research Site

Krakow, Poland
Research Site

Lodz, Poland
Research Site

Olsztyn, Poland
Research Site

Tarnów, Poland
Research Site

Warsaw, Poland
Research Site

Chelyabinsk, Russia
Research Site

Kazan', Russia
Research Site

Moscow, Russia
Research Site

Novosibirsk, Russia
Research Site

Saint Petersburg, Russia
Research Site

Kharkiv, Ukraine
Research Site

Kherson, Ukraine
Research Site

Kropyvnytskyi, Ukraine
Research Site

Lutsk, Ukraine
Research Site

Odesa, Ukraine
Research Site

Poltava, Ukraine
Research Site

Zaporizhzhya, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.